Implants recipients left in the dark when a device maker cuts off support; the real goal for psychedelics researchers and investors

Opinion and perspective curated by First Opinion editor Patrick Skerrett ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

If you or someone you know has a rare disease (more than 25 million Americans are living with one), or are working in this area, check out this upcoming STAT event, "Rare Disease Research: A Prescription," in Washington, D.C. on September 15 from 6:00 pm to 8:30 pm with a rare disease study participant, a member of Congress, a biopharma CEO, and others. Implant recipients shouldn't be left in the dark when a device maker cuts off support By Klaudia Jaźwińska Al Barry/Three Lions/Getty Images Regulators need to act fast to protect individuals who receive cutting-edge medical implants if a company stops supporting its product. Read More Psychedelics researchers and investors should focus on delivering therapy, not drugs By Michael Pollack Adobe Psychedelics by themselves yield minimal healing. Instead, they provide an opening for therapy to help rewire the brain. Read More PCR testing can help clarify confusion over Covid-19 rebound and isolation By Robert B. Darnell PATRICK T. FALLON/AFP via Getty Images By providing quantitative information about Covid-19 infection, PCR testing can help guide isolation and return to school or work policies. Read More Sponsor content by STAT Reports The race for longevity: How scientists are seeking to extend healthy lives In the early 1990s, a biologist’s findings showed that aging, age-related illnesses, and even death were processes directed by genetic programs, raising the tantalizing prospect that they might one day be at least partly controlled by drugs or therapies. Our latest report examines the science behind the longevity industry, exploring what we know about the biology of aging and the various types of interventions scientists are studying to help slow or reverse its corrosive effects. Download now. Will low-dose vaccination stretch the monkeypox vaccine supply, or backfire? By Philip Krause and Luciana L. Borio Mario Tama/Getty Images Using low-dose monkeypox vaccine could stretch the supply, but its effectiveness is uncertain and administration presents challenges. Read More Triple-negative breast cancer highlights the need to act against health inequities By Maimah Karmo National Cancer Institute/Univ. of Pittsburgh Cancer Institute Triple-negative breast cancer tends to affect Black and Hispanic women. Too few of them are aware that it often develops before age 40. Read More Medicare cuts would undermine the movement to increasing in-home care By Krista Drobac Business Insider/AP Medicare's proposal to cut in-home care services not only works against the future but doesn't measure up against its own strategic goals. Read More Addressing institutional trauma in health care: the case for a structured ethical framework By Hans Gutbrod Adobe The Ethics of Political Commemoration offers a framework that can help confront institutional trauma in health care and other domains. Read More FDA needs to fully review ACAM2000 before allowing its widespread use as a monkeypox vaccine By Caitlin Rivers and Tom Inglesby Adobe ACAM2000, a vaccine licensed for smallpox, should not be used to prevent monkeypox without a full review by the FDA and CDC. Read More Why don't they just do what the evidence says? The challenge and promise of implementation science By Mark S. Bauer Adobe Compelling evidence alone may not be enough to improve clinical practice. That's where implementation science comes into play. Read More Decriminalizing HIV: Scientifically proven and morally correct By Mandeep Dhaliwal Niranjan Shrestha/AP The Global Commission on HIV and the Law has helped at least 90 countries advance legal reforms to undo discrimination. Read More Real-world data can help expedite drug approvals for serious diseases with few options By Elenee Argentinis Adobe Connecting real-world data from participants in registration trials can expedite the path to validating effectiveness and safety. Read More Sunday, August 14, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser